STOCK TITAN

Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Ventyx Biosciences (Nasdaq: VTYX) announced that CEO Raju Mohan will present a company overview at the Barclays Global Healthcare Conference on March 16, 2022, from 2:35-3:00 PM ET in Miami, Florida. The management team will also hold investor meetings during the event. Ventyx focuses on developing therapies for inflammatory diseases and autoimmune disorders, with a portfolio that includes VTX958, VTX002, and VTX2735, targeting various conditions. A webcast of the presentation will be available on their website for 30 days post-event.

Positive
  • None.
Negative
  • None.

ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the Barclays Global Healthcare Conference being held March 15-17, 2022.

  • Event: Barclays Global Healthcare Conference
    Location: Miami, Florida
    Date: Wednesday, March 16, 2022
    Time: 2:35-3:00 PM ET

Members of the Ventyx management team will also host investor meetings during the conference.

A webcast of the presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of each event for 30 days.

About Ventyx

Ventyx is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Our clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2 S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit: www.ventyxbio.com.

Investor Relations Contact:
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com


FAQ

When will Ventyx present at the Barclays Global Healthcare Conference?

Ventyx will present on March 16, 2022, from 2:35-3:00 PM ET.

Where is the Barclays Global Healthcare Conference being held?

The conference is being held in Miami, Florida.

What is Ventyx's focus in biopharmaceuticals?

Ventyx focuses on therapies for inflammatory diseases and autoimmune disorders.

What are some products in Ventyx's clinical pipeline?

Ventyx's pipeline includes VTX958, VTX002, and VTX2735.

How can investors access the Ventyx presentation?

The presentation will be webcast on the Ventyx website, available for 30 days after the event.

Ventyx Biosciences, Inc.

NASDAQ:VTYX

VTYX Rankings

VTYX Latest News

VTYX Stock Data

160.87M
67.67M
4.01%
84.94%
12.09%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO